tirofiban (aggrastat) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Tirofiban is a non-peptide antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor. Tirofiban is a reversible, competitive inhibitor of GP IIb/IIIa receptors, exerting its effects via the prevention of the binding of fibrinogen and other ligands, resulting in the inhibition of the last common step of thrombi formation. Tirofiban was discovered by Merck, USA, and was approved by the FDA in 1998 under the trade name AGGRASTAT. AGGRASTAT, in combination with heparin, is indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing percutaneous transluminal coronary angioplasty or atherectomy. AGGRASTAT reduces the risk of ischaemic complications in patients with unstable angina/non-Q-wave myocardial infarction and high-risk patients undergoing revascularisation when used against a background of heparin and aspirin. Furthermore, the drug has an acceptable tolerability profile. Therefore, intravenous tirofiban is likely to be used as an adjunct to heparin and aspirin in patients with acute coronary syndromes including high-risk patients undergoing revascularisation.   NCATS

Chemistry

More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$55.9200 - $91.9600

Australia

$152.1294
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(2s)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid | aggrastat | aggrestat | agrastat | cahill may roberts brand of tirofiban hydrochloride monohydrate | l 700462 | l-700462 | l-700,462 | merck brand of tirofiban hydrochloride monohydrate | merck frosst brand of tirofiban hydrochloride monohydrate | merck sharp & dohme brand of tirofiban hydrochloride monohydrate | mk 383 | mk-383 | msd brand of tirofiban hydrochloride monohydrate | n-(butylsulfonyl)-o-(4-(4-piperidyl)butyl)-l-tyrosine | tirofiban | tirofiban hcl | tirofiban hydrochloride | tirofiban hydrochloride monohydrate | tirofibanum

Organizations (75)

Research & Development (71)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (22)

Approved Indications (2)


 

Acute Coronary Syndrome (approved 1998)

Myocardial Infarction

Experimental Indications - Clinical Trial Phases 1-4 (22)


 

Acute Coronary Syndrome (Phase 4)

Angina, Unstable (Phase 3)

Angioplasty, Balloon, Coronary (Phase 4)

Atherosclerosis (Phase 4)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Coronavirus Infections (Phase 2)

Drugs, Investigational (Phase 1/Phase 2)

Embolism and Thrombosis (Phase 2)

Intracranial Aneurysm (Phase 4)

Ischemic Stroke (Phase 4)

Myocardial Infarction (Phase 4)

Non-ST Elevated Myocardial Infarction (Phase 4)

No-Reflow Phenomenon (Phase 4)

Percutaneous Coronary Intervention (Phase 4)

Pneumonia, Viral (Phase 2)

Renal Insufficiency (Phase 1)

Respiratory Insufficiency (Phase 2)

ST Elevation Myocardial Infarction (Phase 4)

Stroke (Phase 2/Phase 3)

Subarachnoid Hemorrhage (Phase 1/Phase 2)

Thrombolytic Therapy (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 45
  • # of Trial Organizations: 71

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue